A

Arbutus Biopharma Corp
D

ABUS

3.21500
USD
-0.03
(-0.92%)
مغلق
حجم التداول
11,865
الربح لكل سهم
-0
العائد الربحي
-
P/E
-8
حجم السوق
615,759,720
أصول ذات صلة
A
ABEO
-0.10500
(-1.58%)
6.54000 USD
ALNY
ALNY
1.29
(0.39%)
329.01 USD
A
ARWR
-0.520
(-3.20%)
15.740 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
E
EDIT
-0.11000
(-3.38%)
3.14000 USD
F
FATE
-0.01000
(-0.80%)
1.23500 USD
MRNA
MRNA
0.125
(0.37%)
34.145 USD
S
SRPT
-0.970
(-7.53%)
11.910 USD
V
VIR
-0.11000
(-1.91%)
5.65000 USD
V
VKTX
0.960
(2.87%)
34.420 USD
المزيد
الأخبار المقالات

العنوان: Arbutus Biopharma Corp

القطاع: Healthcare
الصناعة: Biotechnology
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.